IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer PDF Download

Author: Ming Sound Tsao
Publisher:
ISBN: 9780983295877
Category :
Languages : en
Pages :

View

Book Description
The IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer is a resource designed to help pathologists, clinicians, other health care personnel, and patients better understand emerging programmed cell death ligand-1 (PD-L1) immunohistochemistry (IHC) assays as well as important areas of clarity and debate.

Author: Bin Yang
Publisher: Springer
ISBN: 331930741X
Category : Medical
Languages : en
Pages : 297

View

Book Description
This book reviews the current applications of molecular tools in cytopathology and provides a concise handbook for those who provide care in this era of personalized medicine. Specifically, the text provides a comprehensive and concise review of the emerging molecular tests available clinically in different subspecialities of diagnostic pathology. It reviews the current data of molecular testing already applied in cytopathology, discusses some of the biomarkers with potential utility in cytopathology in the near future and reviews the technical challenges in applying and validating molecular tools in liquid-based cytologic materials. Molecular Cytopathology will serve as a valuable resource for cytopathologists, cytotechnologists, pathology trainees, and clinicians with an interest in molecular applications in cytopathology.

Author: Steven E. Schild, MD
Publisher: Demos Medical Publishing
ISBN: 1935281801
Category : Medical
Languages : en
Pages : 260

View

Book Description
Thoracic Malignancies: Thoracic Malignancies is the first title in Radiation Medicine Rounds. These tumors take more lives than any others and they are among the most preventable of tumors. Thus it is crucial for the practitioner to be up-to-date on the latest insights regarding their management. Thoracic Malignancies addresses the multi-disciplinary nature of the care of these tumors. There is representation from radiation oncology, medical oncology, and surgery ensuring a well-rounded summarization of current practice. Included are chapters on lung cancer, esophageal cancer, and thymomas providing coverage of the vast majority of thoracic tumors. The multi-disciplinary nature of the articles provides readers with an up-to-date summary and a well-rounded review regarding these tumors and their care. Expert authors provide reviews and assessments of the most recent data and its implications for current clinical practice, along with insights into emerging new trends of importance for the near future. About the Series Radiation Medicine Rounds is an invited review publication providing a thorough analysis of new scientific, technologic, and clinical advances in all areas of radiation medicine. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Published three times a year Radiation Medicine Rounds provides authoritative, thorough assessments of a wide range of Ïhot topicsÓ and emerging new data for the entire specialty of radiation medicine. Features of Radiation Medicine Rounds include: Editorial board of nationally recognized experts across the spectrum of radiation medicine In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Radiation Medicine Issues edited by an authority in specific subject area Focuses on major topics in Radiation Medicine with in-depth articles covering advances in radiation science radiation medicine technology, radiation medicine practice, and assessment of recent quality and outcomes studies Emphasizes multidisciplinary approaches to research and practice

Author: S.E. Monaco
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318023965
Category : Medical
Languages : en
Pages : 147

View

Book Description
This high-yield reference book focuses on the clinical, technical, and pathological aspects of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). Its reviews cover all aspects of EBUS-TBNA, including the clinical perspective, technical aspects of the procedure, and cytomorphology of common and uncommon entities, as well as highlights diagnostic challenges. Each chapter features a multitude of full-color high-resolution images and includes key references to the current literature in the field. Additionally, reference tables and informative figures highlight the salient points. The book is unique in that it is written by experienced thoracic surgeons, pulmonary medicine physicians, and cytopathologists who use EBUS-TBNA in a large medical center. This publication is of interest to individuals learning and practicing cytopathology, in addition to clinicians practicing pulmonary/thoracic medicine or surgery. In short, it provides important pearls of wisdom to create a comprehensive reference for all physicians involved with EBUS-TBNA.

Author: Ming Sound Tsao
Publisher:
ISBN: 9780983295853
Category :
Languages : en
Pages :

View

Book Description
The IASLC Atlas of ALK and ROS1 Testing in Lung Cancer is a resource designed to help pathologists, laboratory scientists, and practicing physicians better understand the background, protocol, and interpretation of results of ALK and ROS1 testing for patients with advanced non-small cell lung cancer.

Author: Philip T. Cagle
Publisher: Springer Science & Business Media
ISBN: 1461431972
Category : Medical
Languages : en
Pages : 217

View

Book Description
As with other books in the Molecular Pathology Library Series, Molecular Pathology of Lung Cancer bridges the gap between the molecular specialist and the clinical practitioner, including the surgical pathologist who now has a key role in decisions regarding molecular targeted therapy for lung cancer. Molecular Pathology of Lung Cancer provides the latest information and current insights into the molecular basis for lung cancer, including precursor and preinvasive lesions, molecular diagnosis, molecular targeted therapy, molecular prognosis, molecular radiology and related fields for lung cancer generally and for the specific cell types. As many fundamental concepts about lung cancer have undergone revision in only the past few years, this book will likely be the first to comprehensively cover the new molecular pathology of lung cancer. It provides a foundation in this field for pathologists, medical oncologists, radiation oncologists, thoracic surgeons, thoracic radiologists and their trainees, physician assistants, and nursing staff.

Author: Bernardo L. Rapoport
Publisher: Karger Medical and Scientific Publishers
ISBN: 3318068187
Category : Medical
Languages : en
Pages : 109

View

Book Description
Cancer is a multifaceted disease in which genetic changes induce uncontrolled tumor growth. Genomic characterization of cancer is now leading to better diagnostic, prognostic and predictive biomarkers, and effective individualized management. 'Fast Facts: Comprehensive Genomic Profiling' provides a crash course in the science, methods and application of genomic profiling. Assuming only the most basic knowledge – or memory – of cell biology, the authors provide an overview of DNA and RNA biology and next-generation sequencing. This sets in context the descriptions of prognostic and predictive biomarkers for different cancer types and genomic-based treatments. Finally, but importantly, some of the practicalities of gaining and interpreting genomic information are described. Whether you need a primer or a refresher, this short colorful book demystifies this complex subject. Contents: • Genetic mutations and biomarkers • Understanding next-generation sequencing • Elements of comprehensive genomic profiles • Role in precision oncology • Predictive and prognostic biomarkers • Overcoming barriers to genotype-directed therapy

Author: Ravi Salgia
Publisher: Springer
ISBN: 3030178323
Category : Medical
Languages : en
Pages : 244

View

Book Description
This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient’s genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.

Author: Henryk A. Domanski
Publisher: Springer Science & Business Media
ISBN: 1447124464
Category : Medical
Languages : en
Pages : 576

View

Book Description
This book covers all of the diagnostic areas where FNAC is used today. This includes palpable lesions and lesions sampled using various radiological methods, and correlations with ancillary examinations detailed on an entity-by-entity basis. As well as being a complete atlas of the facts and findings important to FNAC, this atlas is a guide to diagnostic methods that optimize health care. The interaction of the cytologist or cytopathologist with other specialists (radiologists, oncologists and surgeons) involved in the diagnosis and treatment of patients with suspicious mass lesions is emphasized and illustrated throughout. With contributions from experts in the field internationally and abundant colour images Atlas of Fine Needle Aspiration Cytology provides a comprehensive and up-to-date guide to FNAC for pathologists, cytopathologists, radiologists, oncologists, surgeons and others involved in the diagnosis and treatment of patients with suspicious mass lesions.

Author: Marianne Davies
Publisher: Springer
ISBN: 3030165507
Category : Medical
Languages : en
Pages : 122

View

Book Description
This book aims to educate nurses and advanced practice providers (APP’s) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP’s are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents. Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers. To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP’s with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the next level of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations. With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment.